EW

Edwards Lifesciences Corp

Add to Watchlist

Advanced Chart

78.610

-0.63(-0.795%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

79.630

Open

79.165

VWAP

78.61

Vol

3.96M

Mkt Cap

46.11B

Low

77.640

Amount

311.58M

EV/EBITDA(TTM)

25.41

Total Shares

602.60M

43.24B

EV/OCF(TTM)

P/S(TTM)

8.29

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

1.55B

+9.65%

0.656

+2.55%

1.54B

+11.19%

0.606

+2.67%

1.49B

+10.3%

0.585

-12.7%

Estimates Revision

The market is revising Upward the revenue expectations for Edwards Lifesciences Corporation (EW) for FY2025, with the revenue forecasts being adjusted by 1.33% over the past three months. During the same period, the stock price has changed by 4.76%.

Revenue Estimates for FY2025

Revise Upward

+1.33%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.96%

In Past 3 Month

Stock Price

Go Up

+4.76%

In Past 3 Month

19 Analyst Rating

6.69% Upside

Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 83.87 USD with a low forecast of 75.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

9 Hold

0 Sell

Moderate Buy

6.69% Upside

Current: 78.610

Low

75.00

Averages

83.87

High

95.00

6.69% Upside

Current: 78.610

Low

75.00

Averages

83.87

High

95.00

Daiwa

Neutral -> Outperform

upgrade

$89

2025-07-29

Reason

Daiwa

Price Target

$89

2025-07-29

upgrade

Neutral -> Outperform

Reason

Daiwa upgraded Edwards Lifesciences to Outperform from Neutral with an $89 price target.

BTIG

Neutral -> Buy

upgrade

$100

2025-07-29

Reason

BTIG

Price Target

$100

2025-07-29

upgrade

Neutral -> Buy

Reason

BTIG upgraded Edwards Lifesciences to Buy from Neutral with a $100 price target. The firm cites improving stability in the company's transcatheter aortic valve replacements segment and its positive U.S. doctor feedback on the upcoming catalysts for the upgrade. Edwards' business performance has been improving steadily in recent months, the analyst tells investors in a research note. BTIG likes the setup for the company's U.S. TAVR sales and points out that management discussed catalysts like the asymptomatic TAVR launch and a potential update to the TAVR National Coverage Determination that may enable more adoption of the procedure.

Piper Sandler

Overweight

maintain

$83 -> $90

2025-07-25

Reason

Piper Sandler

Price Target

$83 -> $90

2025-07-25

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Edwards Lifesciences to $90 from $83 and keeps an Overweight rating on the shares. The firm notes the company reported strong Q2 results posting a top- and bottom-line beat. Piper was pleased to see the FY2025 TAVR growth guidance increased to +6%-7% year-over-year, and believes this speaks to a handful of tailwinds at the back of this business.

Deutsche Bank

Buy

maintain

$85 -> $94

2025-07-25

Reason

Deutsche Bank

Price Target

$85 -> $94

2025-07-25

maintain

Buy

Reason

Deutsche Bank raised the firm's price target on Edwards Lifesciences to $94 from $85 and keeps a Buy rating on the shares.

JPMorgan

Neutral

maintain

$80 -> $85

2025-07-25

Reason

JPMorgan

Price Target

$80 -> $85

2025-07-25

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Edwards Lifesciences to $85 from $80 and keeps a Neutral rating on the shares. The company reported better than expected Q2 results which will help bring confidence in its growth over the back half of the year, the analyst tells investors in a research note.

RBC Capital

Outperform

maintain

$85 -> $89

2025-07-25

Reason

RBC Capital

Price Target

$85 -> $89

2025-07-25

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Edwards Lifesciences to $89 from $85 and keeps an Outperform rating on the shares. Edwards delivered sales and EPS upside and raised the low end of 2025 revenue guidance, noting confidence at the high end of EPS, the analyst tells investors in a research note. The current sentiment and valuation support upside, the firm says.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Edwards Lifesciences Corp (EW.N) is 30.67, compared to its 5-year average forward P/E of 35.41. For a more detailed relative valuation and DCF analysis to assess Edwards Lifesciences Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

35.41

Current PE

30.67

Overvalued PE

42.30

Undervalued PE

28.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

27.86

Current EV/EBITDA

23.49

Overvalued EV/EBITDA

33.41

Undervalued EV/EBITDA

22.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

9.36

Current PS

7.46

Overvalued PS

11.45

Undervalued PS

7.26